Pharma Equity Group Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Pharma Equity Group's earnings have been declining at an average annual rate of -163.4%, while the Real Estate industry saw earnings growing at 1.7% annually.
Key information
-163.4%
Earnings growth rate
-135.0%
EPS growth rate
| Real Estate Industry Growth | 27.6% |
| Revenue growth rate | n/a |
| Return on equity | -119.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Pharma Equity Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -31 | 19 | 10 |
| 31 Mar 24 | 0 | -29 | 18 | 11 |
| 31 Dec 23 | 0 | -25 | 16 | 9 |
| 30 Sep 23 | 0 | -14 | 9 | 8 |
| 30 Jun 23 | 0 | -12 | 7 | 6 |
| 31 Mar 23 | 0 | -10 | 7 | 5 |
Quality Earnings: PEG is currently unprofitable.
Growing Profit Margin: PEG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if PEG's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare PEG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEG is unprofitable, making it difficult to compare its past year earnings growth to the Real Estate industry (5.6%).
Return on Equity
High ROE: PEG has a negative Return on Equity (-118.97%), as it is currently unprofitable.